Video

Dr. Peters on Creating Algorithms for Personalized Therapy in NSCLC

Solange Peters, MD, PhD, of University Hospital Center Vaudois and Lausanne University in Switzerland, discusses the rapid advances in the lung cancer field and the importance of using biomarkers to create personalized immunotherapy treatments for patients.

Solange Peters, MD, PhD, of University Hospital Center Vaudois and Lausanne University in Switzerland, discusses the rapid advances in the lung cancer field and the importance of using biomarkers to create personalized immunotherapy treatments for patients.

In the past 3 to 5 years, the treatment paradigm of non—small cell lung cancer has completely changed, creating long-term survivor outcomes in metastatic disease and a number of novel treatment options, explains Peters. All patients should receive immunotherapy, ideally in the frontline setting, she explains.

There should be a heavier focus on precision oncology in NSCLC, including defining biomarkers for improved patient selection and understanding predictive factors to treatment. Creating algorithms for personalized immunotherapy will take some time, but Peters believes it is important in creating effective treatment. For sequencing, Peters recommends using single-agent or combination immunotherapy to treat patients with early-stage disease.

<<< 2019 International Lung Cancer Congress

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO